JSPR, US4718712023

Jasper Therapeutics approves reverse split for Jasper Therapeutics stock

Published on 10/05/2026 at 20:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The meeting represented 21,747,865 shares, or 65.36 percent of the total. Jasper Therapeutics stock trades at USD 0.57 versus USD 2.69 high.

JSPR, US4718712023, Illustration mit AI erstellt.

Jasper Therapeutics, Inc. (ISIN US4718712023) secured approval for a reverse stock split ranging from 1-for-15 to 1-for-35, giving the board discretion to choose the ratio by December 31, 2026. The company disclosed the vote in a Form 8-K dated October 5, 2026, filed after its September 30 special meeting through StockTitan.

Shareholder vote clears split range

The meeting represented 21,747,865 shares, equal to 65.36 percent of the 33,274,561 shares outstanding on the August 10, 2026 record date. Each of the three proposals received approval, including the reverse split and an increase in authorized common shares from 490.0 million to 675.0 million, according to the filing.

The board can select any ratio between 1-for-15 and 1-for-35 without seeking another shareholder vote. That flexibility gives Jasper room to adjust the share count while addressing the trading-price requirements attached to its Nasdaq listing.

Cash position remains the market question

Jasper describes itself as a clinical-stage biotechnology company developing therapies for immune-mediated diseases. Its pipeline includes KP-104, briquilimab and KP-701, with programs spanning complement inhibition, stem-cell transplant conditioning and antibody-mediated disorders, according to the company's investor-relations profile at Jasper Therapeutics.

The corporate action comes alongside a leadership change. Investing.com reported on September 28, 2026, that CFO Herb Cross would resign effective October 9, 2026, with interim finance appointments taking effect afterward.

JSPR remains near its yearly low

Jasper Therapeutics stock was trading at USD 0.57 on Nasdaq on October 5, 2026 at 2:27 p.m. ET. Its market capitalization was USD 9.3 million, while the 52-week range stood at USD 0.32 to USD 2.69. The current price is USD 2.12 below the yearly high, a 78.81 percent gap calculated against that high.